Title:
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO/2010/059575
Kind Code:
A3
Abstract:
The present invention provides methods of sensitizing lung cancer cells to cisplatin and inhibiting the growth of lung cancer tumors by employing a modified eIF-4E antisense oligonucleotide and cisplatin in combination.
Inventors:
GRAFF JEREMY RICHARD (US)
Application Number:
PCT/US2009/064666
Publication Date:
September 23, 2010
Filing Date:
November 17, 2009
Export Citation:
Assignee:
ISIS PHARMACEUTICALS INC (US)
GRAFF JEREMY RICHARD (US)
GRAFF JEREMY RICHARD (US)
International Classes:
A61K31/282; A61K31/7088; A61K31/7125; A61P35/00
Domestic Patent References:
| WO2005028628A2 | 2005-03-31 |
Other References:
DONG KE ET AL: "Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.", BREAST CANCER RESEARCH AND TREATMENT FEB 2009 LNKD- PUBMED:18327707, vol. 113, no. 3, 10 March 2008 (2008-03-10), pages 443 - 456, XP002593842, ISSN: 1573-7217
ORIDATE N ET AL: "Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin", CANCER BIOLOGY AND THERAPY 200503 US, vol. 4, no. 3, March 2005 (2005-03-01), pages 318 - 323, XP002593841
SEKI N ET AL: "Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung", CLINICAL CANCER RESEARCH 20021001 US, vol. 8, no. 10, 1 October 2002 (2002-10-01), pages 3046 - 3053, XP002593844, ISSN: 1078-0432
LEE MYOUNG WOO ET AL: "Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 MAY 2008 LNKD- PUBMED:18224693, vol. 122, no. 10, 15 May 2008 (2008-05-15), pages 2380 - 2384, XP002593843, ISSN: 1097-0215
GRAFF J R ET AL: "Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without tox", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI32044, vol. 117, no. 9, 4 September 2007 (2007-09-04), pages 2638 - 2648, XP002572954, ISSN: 0021-9738
WANG G ET AL: "MOLECULAR BASIS OF CELLULAR RESPONSE TO CISPLATIN CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (REVIEW)", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 12, no. 5, 1 November 2004 (2004-11-01), pages 955 - 965, XP009053038, ISSN: 1021-335X
KHOURY THAER: "Eukaryotic initiation factor-4E (eIF-4E) and cyclin D1 expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 1279, XP002593845, ISSN: 0197-016X
ORIDATE N ET AL: "Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin", CANCER BIOLOGY AND THERAPY 200503 US, vol. 4, no. 3, March 2005 (2005-03-01), pages 318 - 323, XP002593841
SEKI N ET AL: "Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung", CLINICAL CANCER RESEARCH 20021001 US, vol. 8, no. 10, 1 October 2002 (2002-10-01), pages 3046 - 3053, XP002593844, ISSN: 1078-0432
LEE MYOUNG WOO ET AL: "Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 MAY 2008 LNKD- PUBMED:18224693, vol. 122, no. 10, 15 May 2008 (2008-05-15), pages 2380 - 2384, XP002593843, ISSN: 1097-0215
GRAFF J R ET AL: "Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without tox", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI32044, vol. 117, no. 9, 4 September 2007 (2007-09-04), pages 2638 - 2648, XP002572954, ISSN: 0021-9738
WANG G ET AL: "MOLECULAR BASIS OF CELLULAR RESPONSE TO CISPLATIN CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (REVIEW)", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 12, no. 5, 1 November 2004 (2004-11-01), pages 955 - 965, XP009053038, ISSN: 1021-335X
KHOURY THAER: "Eukaryotic initiation factor-4E (eIF-4E) and cyclin D1 expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 1279, XP002593845, ISSN: 0197-016X
Attorney, Agent or Firm:
INSOGNA, Anthony, M. (222 East 41st StreetNew York, NY, US)
Download PDF: